

December 10, 2024

## COVERAGE OF ZURZUVAE ON THE TEXAS FORMULARY

### BACKGROUND

Zurzuvaе is approved by the Food and Drug Administration (FDA) and is indicated for the oral treatment of postpartum depression (PPD) in adults. Currently, Zurzuvaе is available on the Texas Medicaid Formulary as a non-preferred drug and requires a preferred drug list (PDL) prior authorization.

### KEY DETAILS

Zurzuvaе requires a PDL prior authorization due to non-preferred status. Providers may initiate the prior authorization process for non-preferred drugs to provide information or documentation supporting at least one PDL exception criteria.

HHSC received complaints that providers are experiencing difficulty obtaining prior authorization for Zurzuvaе. MCOs may allow Zurzuvaе coverage if the provider submits appropriate supporting information or documentation. HHSC encourages MCOs to work with Medicaid providers to resolve the PDL prior authorization requests and approve coverage for Zurzuvaе when at least one PDL exception criteria is met.